Screener / SEC EDGAR /CIK 0001745999 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Beam Therapeutics Inc. BEAM

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of BEAM's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Jul 20, 2023
Questions asked 19 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 19 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 84 days or less from the first letter to the closing letter.

Form 10-K for the Year Ended December 31, 2022

2023-07-20 to 2023-10-12 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2023-10-12
Risk factors
Notes to Consolidated Financial Statements
SEC asked
Equity method investment Orbital, page F-26 1. Please address the following as it relates to your equity method investment in Orbital Therapeutics: • Reconcile your disclosure that you received a 31.5% fully diluted equity interest in Orbital at the time of your initial investment and that of December 31, 2022 you hold 95.8% of its outstanding common stock with your risk factor disclosure on page 77 whereby you
Rest of the question

state that you hold a "minority interest" in Orbital. • Provide us with your analysis under ASC 810 supporting your determination that you are not the primary beneficiary of Orbital. As part of your response, identify the activities of Orbital that most significantly impact its economic performance and explain how you determined that you do not have the power to direct such activities and therefore do not hold a controlling financial interest. • Explain how the interim management services you are providing Orbital in addition to your board representation factored into your analysis. • To the extent that the power is shared among the various variable interest holders, clarify whether there is a tie-breaking mechanism in place with respect to key decision making.

BEAM answered
Beam respectfully acknowledges the Staff’s comment and has included each of the Staff’s requests in italics below, followed by Beam’s response to the Staff.

Reconcile your disclosure that you received a 31.5% fully diluted equity interest in Orbital at the time of your initial investment and that of December 31, 2022 you hold 95.8% of its outstanding common stock with your risk factor disclosure on page 77 whereby you state that you hold a “minority interest” in Orbital.

In September 2022, Beam contributed exclusive and non-exclusive licenses and certain services to Orbital
Rest of the answer

Therapeutics,

Inc. (“Orbital”) in exchange for 75,000,000 shares of Orbital’s common stock, which at the time of the initial investment constituted 97.1% of the outstanding common stock of Orbital (77,245,830 common shares). In addition to outstanding common stock, Orbital’s capital structure consisted of outstanding preferred stock (102,733,126), and unvested restricted common stock and common stock options (58,214,170 in aggregate). Accordingly, on a fully diluted basis, which takes into account the securities that are convertible into common stock or could be common stock outstanding when vested, Beam’s investment in Orbital represented 31.5% of Orbital’s equity.

Due to the subsequent issuance of shares of common stock, Beam held 95.8% of the outstanding common stock as of December 31, 2022. In light of the voting rights of the outstanding preferred stock and restricted stock, Beam’s interest in Orbital is a noncontrolling interest, which we referred to as a “minority interest” in the risk factor disclosure.

Because Beam accounts for its investment in Orbital under the equity method of accounting, it is required to recognize its share of Orbital’s earnings or losses based on its share of the outstanding common stock and in-substance common stock. Beam determined the other classes of Orbital equity do not represent in-substance common stock in accordance with ASC 323-10-15-13.

beneficiary of Orbital. As part of your response, identify the activities of Orbital that most significantly impact its economic performance and explain how you determined that you do not have the power to direct such activities and therefore do not

Explain how the interim management services you are providing Orbital in addition to your board representation factored into your analysis.

To the extent that the power is shared among the various variable interest holders, clarify whether there is a tie-breaking mechanism in place with respect to key decision making.

Upon investing in Orbital,

Beam assessed the accounting for its investment in accordance with ASC 810-10, Consolidation - Overall. After determining that no scope exception applies under the guidance of ASC 810-10-15-12 and ASC

810-10-15-17, Beam concluded that it has a variable interest in Orbital through its investment in Orbital common stock. Because

Orbital does not have sufficient equity to finance its activities without additional subordinated financial support, Beam concluded that Orbital is a variable interest entity (“VIE”) in accordance with ASC 810-10-15-14(a) and is subject to potential consolidation under the VIE model. Although Beam is not subject to the voting interest model, Beam notes it does not have voting control under the voting interest model. As analyzed further below, Beam also does not have control under the VIE model.

To evaluate potential consolidation under the variable interest model, Beam (1) evaluated the purpose and design of the VIE and the risks the VIE was designed to create and pass along to its variable interest holders; (2) identified the activities related to the risks identified in step 1 that most significantly affect the economic performance of the VIE; and (3) identified the party that makes the significant decisions or controls the activity or activities that most significantly affect the VIE’s economic performance, including whether any other parties have involvement in those decisions (shared power).

Orbital was initially designed to develop ribonucleic acid (“RNA”)-based therapeutic products, and the primary risks are the operational and financial risks related to a new business in a developing area of science. More specifically, Orbital’s economic performance is dependent on research and development activities and future commercialization of its technology. Accordingly, the activities related to these risks that most significantly impact Orbital’s economic performance are the decisions relating to the funding, oversight, and execution of research and development activities, which are encapsulated in the operating plan and budget and the personnel of Orbital.

Beam determined the following activities most significantly impact Orbital’s economic performance:

(1) approval of the operating plan and budget, including determination of which research and development programs to pursue and how to develop the corresponding intellectual property, (2) hiring and firing of management and

(3) determination of management’s compensation.

To assess which party has the power to direct these activities, Beam considered Orbital’s key governance documents, including the articles of incorporation, by-laws, investor rights agreement and voting agreement. Decisions related to the significant activities that most impact the economic performance of Orbital are made by the Orbital board of directors on behalf of the equity holders. Although there is an executive team led by a CEO running the day-to-day operations, the Orbital board has responsibility for the overall direction, supervision and management of Orbital. Orbital’s board was initially comprised of six directors and Beam has the right to nominate one out of six directors for approval by the preferred shareholders. Further, Beam’s President, who was serving as the interim CEO of Orbital, is also entitled to serve as a director of Orbital’s board. As noted above, all activities that most significantly impact Orbital’s economic performance are directed by the Orbital board and the board approves decisions by a simple majority. Based on the board composition, Beam determined that no one party has control over the Orbital board and power is not shared because the activities that most significantly affect Orbital’s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Orbital board. Therefore, because Beam controls no more than two out of six of Orbitals’ directors, Beam cannot unilaterally direct any of the activities that most significantly impact Orbital’s economic performance. Accordingly, Beam is not the primary beneficiary of the VIE and need not consolidate Orbital.

Beam considered whether the interim management services provided by Beam employees to Orbital provided Beam with the power to make decisions about the significant activities identified above. The interim CEO of Orbital serves at the direction of the

Orbital board. That is, the interim CEO does not have any contractual, super voting rights to individually make any decisions about the activities that most significantly impact the economic performance of Orbital. In addition, the CEO is subject to substantive oversight by the Orbital board, as described further below. There is no contractual obligation to keep Beam’s employee as interim CEO for a specified period of time. Furthermore, the role of the CEO is hired and fired by the Orbital board with no approval required from Orbital equity holders. Therefore, Beam does not have the power to require Orbital to keep its employee as interim CEO. In addition to the interim CEO, certain of Beam’s employees were engaged by

Orbital to provide consulting services to Orbital while Orbital expanded its employee hiring. Similar to the interim CEO, these individuals are involved in the conduct of certain day-to-day activities in accordance with the operating plan and cannot deviate from the operating plan without approval from the Orbital board. Accordingly, the interim management services provided by Beam’s employees did not provide Beam with the power to direct the activities that most significantly impact the economic performance of Orbital.

As stated above, the Orbital business is directed, managed, and controlled by the Orbital board. Further, the board is composed of six directors, and the decisions that most significantly impact the economic performance require only simple majority approval of the board. Therefore, not all parties with board representation are required to approve all the activities that most significantly affect

Orbital’s economic performance. Hence, the power is not shared among variable interest holders and there is no tie-breaking mechanism in place with respect to key decisions.

In addition to power not being shared, Orbital and Beam are not under common control and there is not a single decision maker. Additionally, none of the other conditions to apply the related party guidance in ASC 810-10-25-44B are met. Based on these circumstances, the related party tie-breaker test is not applicable.

Read in the reply
Notes to Consolidated Financial Statements
SEC asked
Equity method investment Orbital, page F-26 1. Please address the following as it relates to your equity method investment in Orbital Therapeutics and your response to our prior comment: • You state that the activities that most significantly impact Orbital’s economic performance are directed by the Orbital board and that power is not shared because the activities that most significantly affect Orbital’s economic
Rest of the question

performance do not require the consent of all of the parties, but rather a simple majority. Given the board consists of six members, explain how key decisions are made when a simple majority vote is not achieved (i.e., 3-3 tie). • You state that Orbital’s board was initially comprised of six directors and that you control no more than two of these seats. Explain how the remaining seats on the Orbital board are determined and identify the parties that have the power to nominate such directors. • You indicate that, in addition to your President who is serving as interim CEO of Orbital, you have the power to nominate one director for approval by the preferred shareholders. Explain the process by which director nominations are approved by preferred shareholders, including the minimum votes needed for approval and how votes are allocated amongst preferred shareholders. • Provide us with both the initial and current composition of Orbital's ownership structure, including both preferred and common shareholders and any other variable interests. In this regard, we note that Orbital was initially funded by ARCH Venture Partners, a16z Bio+Health and Newpath Partners. • For each preferred stockholder, provide us the percentage ownership of Orbital, particularly noting if any one stockholder or group of related party stockholders own a significant percentage of the total preferred stock. If any of the preferred stockholders of Orbital are related parties to you or other preferred stockholders, provide an analysis under ASC 810-10-25-42 through 25-44B. • You state on page 77 of the 10-K that in addition to your CEO and President being members of the board of directors of Orbital, two of your directors affiliated with ARCH Venture Partners are members of the board of directors of Orbital. Tell us how you considered these directors in your determination of whether or not you are the primary beneficiary and whether or not these directors are considered de facto agents pursuant to ASC 810-10-25-43. • Provide us with copies of the following documents to facilitate our analysis:o License and Research Collaboration Agreement entered into with Orbital in September 2022 o Stock Purchase Agreement for purchase of 75.0 million shares of Orbital common stock with a fair value of $25.5 million o Key governance documents for Orbital (e.g., articles of incorporation, by- laws, investor rights agreement and voting agreement) to the extent they contain information relevant to an analysis under ASC 810.

BEAM answered
Beam respectfully acknowledges the Staff’s comment and has included each of the Staff’s requests in bold italics below, followed by Beam’s response to the Staff. As explained in greater detail below, Beam has concluded that it does not have a controlling financial interest in Orbital Therapeutics, Inc. (“Orbital”) and therefore should not consolidate Orbital in Beam’s financial statements at the date of the investment or any time thereafter.
Rest of the answer

In short, Beam does not have the power to direct the activities of Orbital, either through equity ownership, positions on the Orbital board of directors or otherwise. The decisions that most significantly impact the economic performance of Orbital are made by the Orbital board of directors. For accounting purposes, Beam controls the two Orbital board seats held by Beam officers. But Beam controls only two of the six seats of the Orbital board of directors and does not control any other party on the Orbital board of directors. All decisions that most significantly affect Orbital’s economic performance are made by the Orbital board of directors by a simple majority vote and there are no other means for Beam to control the Orbital board of directors. Accordingly, Beam does not have the power to direct the activities of Orbital.

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #1

Beam also considered the potential implications of related parties in the accounting analysis. The related parties as defined under ASC 810 (which includes de facto agents) are affiliated with Arch Venture Partners (“Arch”), a third-party investor in Orbital. Two of Orbital’s directors are designated by Arch, one of whom is a Beam director. A third Orbital director was designated by [**], who is both a member of Beam’s board of directors and a venture partner with Arch. Beam controls neither Arch nor any of these other Orbital directors. Arch does not control Beam and they are not under common control. The final Orbital director is not related to Beam or Arch. Accordingly, Beam’s relationships do not permit Beam to control significant decisions of Orbital.

Beam Therapeutics Inc. respectfully requests that the information contained in Request #1 be treated as confidential information and that the Commission provide timely notice to Terry-Ann Burrell, Chief Financial Officer and Treasurer, Beam Therapeutics Inc., 238 Main Street, Cambridge, MA 02142, phone 857-327-8775, before it permits any disclosure of the bracketed information contained in Request #1.

Having concluded that Beam lacks the power to direct the activities of Orbital that most significantly affect

Orbital’s economic performance (the “power criterion”), Beam also analyzed the extent to which it should apply the so-called related party “tiebreaker test” of ASC 810-10-25-44, which where applicable may identify the primary beneficiary of a variable interest entity from among a group of related parties. Under ASC 810, Beam would not apply the related party “tiebreaker test” unless (i) there is a single decision maker that has met the power criterion but lacks the obligation to absorb losses from or the right to receive benefits of Orbital that could potentially be significant to Orbital (the “economics criterion”), and the aggregation of entities under common control with the single decision maker have met the economics criterion or (ii) they share the power with respect to Orbital. Neither of these required conditions is satisfied. First, no single decision maker met the power criterion because no entity appoints a majority of the directors to the Orbital board of directors. The Orbital board controls the Orbital business activities and the voting rights and Orbital board seats held by each party represent less than the simple majority required for board action. Second, for the purposes of ASC 810, power is not shared among the Beam related parties because unanimous consent of all the parties is not required to make significant decisions.

For these reasons, Beam has concluded that it is not the primary beneficiary with respect to Orbital and should not consolidate Orbital. Beam’s response to the Staff’s detailed questions is below.

You state that the activities that most significantly impact Orbital’s economic performance are directed by the Orbital board and that power is not shared because the activities that most significantly affect Orbital’s economic performance do not require the consent of all of the parties, but rather a simple majority. Given the board consists of six members, explain how key decisions are made when a simple majority vote is not achieved (i.e., 3-3 tie).

Orbital is a company incorporated under the laws of Delaware. Under Delaware law, Orbital’s certificate of incorporation, and Orbital’s bylaws, there are no decisions that require unanimous written consent and none that require greater than majority consent from board members at a meeting. Only a majority vote is required for the matters that significantly impact the economic performance of Orbital. In addition, Orbital has not delegated any key decision-making authority to management or to committees of its board of directors, nor has Orbital adopted any provisions in its certificate of incorporation or bylaws to alter the default decision making procedures under Delaware law. Therefore, all key decisions of Orbital that most significantly affect Orbital’s economic performance are made either by a majority vote of its board at a meeting or, if the board of Orbital so determines, by unanimous written consent of the Orbital board in lieu of a meeting. No affirmative action on any key matters can be validly taken by Orbital when a majority vote (or unanimous written consent) is not achieved, including in instances of a 3-3 tie. No action will be approved where there is a

3-3 tie, and because Beam controls no more than two seats, Beam does not have the power to break a tie, much less control the outcome in the first instance.

You state that Orbital’s board was initially comprised of six directors and that you control no more than two of these seats. Explain how the remaining seats on the Orbital board are determined and identify the parties that have the power to nominate such directors.

In accordance with Orbital’s certificate of incorporation, as well as the Amended and Restated Voting Agreement to which Orbital, Beam and substantially all Orbital stockholders are a party (the “Voting Agreement”), Orbital’s board was initially comprised of six directors. The two board seats that are considered to be controlled by Beam for purposes of the accounting analysis are designated and elected as follows:

One director (the “Orbital CEO Designee”) is designated by virtue of serving as Orbital’s Chief

Executive Officer and is elected by the majority of the Orbital common stockholders. On September 2, 2022, (the date of Beam’s investment in Orbital), and also on December 31, 2022, the position of Orbital’s Chief Executive

Officer was held on an interim basis by Beam’s President. Accordingly, for accounting purposes, the Orbital CEO Designee board seat has been considered to be controlled by Beam for as long as such board seat is held by a member of Beam’s executive team and Beam holds a majority of the Orbital common stock.

One director (the “Beam Designee”) is designated by Beam and is elected by the majority of the Orbital preferred stockholders (please refer to Beam’s response to the Staff below for a summary of the significant preferred stockholders). On September 2, 2022, and also on December 31, 2022, the Beam Director Designee was Beam’s Chief

Executive Officer. Accordingly, for accounting purposes, the Beam Designee board seat is considered to be controlled by Beam.

The remaining four board seats that are not considered to be controlled by Beam are designated and elected as follows:

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #2

Two directors (the “Arch Designees”) are designated by Arch, the lead investor in Orbital’s

September 2022 preferred stock financing (the “Series Seed round”), and are elected pursuant to the Voting Agreement by the majority of the Orbital preferred stockholders.

One director (the “a16z Designee”) is designated by a16z Bio+Health (“a16z”), another participant in the Series Seed round, and is elected pursuant to the Voting Agreement by the majority of the Orbital preferred stockholders.

One director (the “Orbital Board Preferred Designee”) is designated by [**] and is elected pursuant to the Voting Agreement by the majority of the Orbital preferred stockholders.

Beam Therapeutics Inc. respectfully requests that the information contained in Request #2 be treated as confidential information and that the Commission provide timely notice to Terry-Ann Burrell, Chief Financial Officer and Treasurer, Beam

Therapeutics Inc., 238 Main Street, Cambridge, MA 02142, phone 857-327-8775, before it permits any disclosure of the bracketed information contained in Request #2.

Each Orbital stockholder party to the Voting Agreement is contractually obligated, at any meeting of Orbital stockholders at which an election of directors is held, or pursuant to any written consent of Orbital stockholders, to vote all shares owned by such stockholder or over which such stockholder has voting control in favor of individuals designated above.

For accounting purposes under ASC

810-10-25-43(c), related parties include de facto agents of a reporting entity (e.g., Beam) and includes “[a]n officer, employee, or member of the governing board of the reporting entity.” As such, the Orbital CEO Designee, the Beam Designee, the Arch Designees, and the Orbital Board Preferred Designee are considered related parties pursuant to ASC 810-10-25-43(c) of Beam in the accounting analysis. The a16z Designee is not a related party.

You indicate that, in addition to your President who is serving as interim CEO of Orbital, you have the power to nominate one director for approval by the preferred shareholders. Explain the process by which director nominations are approved by preferred shareholders, including the minimum votes needed for approval and how votes are allocated amongst preferred shareholders.

Under Orbital’s certificate of incorporation, on September 2, 2022 (the date of Beam’s investment in Orbital) and also on December 31,

2022, the holders of record of preferred stock, voting exclusively and as a separate class, are entitled to elect five directors of Orbital (each a “Preferred Director”); and the holders of record of the shares of common stock (excluding shares of common stock issued or issuable upon conversion of shares of preferred stock), voting exclusively and as a separate class, are entitled to elect one director of Orbital (the “Common Director”). Orbital’s certificate of incorporation does not provide for cumulative voting, and each director of Orbital is elected by the majority vote of the class or classes of stockholders entitled to vote for such director. As a result, the affirmative vote of a majority of the holders of Preferred Stock is necessary for the election of each of the five Preferred Directors, and the affirmative vote of a majority of the holders of common stock is necessary for the election of the Orbital CEO Designee as the Common Director.

Under the Voting Agreement, each Orbital stockholder is contractually obligated, at any meeting of Orbital stockholders at which an election of directors is held, or pursuant to any written consent of Orbital stockholders, to vote all shares owned by such stockholder or over which such stockholder has voting control in favor of individuals designated from time to time by certain parties to the Voting Agreement.

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request

#3

As described in the response to the previous comment, (i) the Beam Designee is designated for election as a Preferred Director by Beam,

(ii) the two Arch Designees are designated for election as Preferred Directors by entities affiliated with Arch, (iii) the a16z Designee is designated for election as a Preferred Director by a16z, (iv) the Orbital Board Preferred

Designee is designated for election as a Preferred Director by [**], and (v) the Orbital CEO Designee is designated for election as the Common Director. Orbital’s Chief Executive Officer is hired and removed by the Orbital board (subject to a simple majority vote of the Orbital board) with no approval for his or her hiring or removal required from Orbital equity holders.

Beam Therapeutics Inc. respectfully requests that the information contained in Request #3 be treated as confidential information and that the Commission provide timely notice to Terry-Ann Burrell, Chief Financial Officer and Treasurer, Beam Therapeutics Inc., 238 Main Street, Cambridge, MA 02142, phone 857-327-8775, before it permits any disclosure of the bracketed information contained in Request #3.

Provide us with both the initial and current composition of Orbital’s ownership structure, including both preferred and common shareholders and any other variable interests. In this regard, we note that Orbital was initially funded by ARCH Venture Partners, a16z Bio+Health and Newpath Partners.

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #4

On September 2, 2022, Orbital’s capital structure consisted of common stock, Series Seed Preferred Stock, unvested restricted common stock and common stock options. There are no relevant variable interests in Orbital other than equity interests because only the equity interests have the right to make decisions that most significantly impact the entity. The License and Research

Collaboration Agreement between Beam and Orbital dated September 2, 2022 (the “License Agreement”) is not a variable interest because [**]. In addition, the License Agreement does not provide Beam with any rights to direct the activities at Orbital beyond the rights provided in Orbital’s governance documents to holders of Orbital common stock. Other license agreements to which Orbital is a party similarly do not provide any governance rights. As noted above, all of the significant Orbital activities are subject to approval by the Orbital board.

As of September 2, 2022, Orbital’s ownership structure is as follows:

Shareholder

Common

Stock1

Series Seed

Preferred

Stock2

Fully

Diluted

Shares

Interest

Interest in

Stock

Beam Therapeutics

75,000,000

—

31.5

%

0.0

ARCH Venture Partners

[**]

Giuseppe (Pino) Ciaramella a16z

Newpath

Outstanding Options

Total

135,574,000

102,733,126

238,307,126

100

Common stock includes both common stock, which is outstanding for accounting purposes, and [**]. The [**] are not considered outstanding shares for accounting purposes (i.e., Beam’s application of the equity method of accounting considered only the [**] common shares). Accordingly, as of September 2, 2022, Beam held 75,000,000 of the total

77,245,830 shares of common stock outstanding for accounting purposes, representing 97% of such shares.

Total Series Seed Preferred Stock includes [**] shares of [**] preferred stock, [**], that vest over time.

The only change to Orbital’s capitalization between September 2 and December 31, 2022, was due to [**]. As a result,

Beam’s share of outstanding common stock on December 31, 2022 was [**]%.

During the first half of 2023, Orbital issued an aggregate [**] shares of Series A Preferred Stock to Arch, a16z, Newpath Partners and other investors. Beam did not participate in the Series A financing and as a result, its ownership interest in Orbital was diluted. In connection with Orbital’s Series A financing, the [**].

As of August 29, 2023, Orbital’s ownership structure is as follows:

Series A

16.8

102,642,681

100%

Beam’s share of the outstanding common stock on August 29, 2023, [**].

Beam Therapeutics Inc. respectfully requests that the information contained in Request #4 be treated as confidential information and that the Commission provide timely notice to Terry-Ann Burrell, Chief Financial Officer and Treasurer, Beam Therapeutics Inc., 238 Main Street, Cambridge, MA 02142, phone 857-327-8775, before it permits any disclosure of the bracketed information contained in Request #4.

For each preferred stockholder, provide us the percentage ownership of Orbital, particularly noting if any one stockholder or group of related party stockholders own a significant percentage of the total preferred stock. If any of the preferred stockholders of Orbital are related parties to you or other preferred stockholders, provide an analysis under ASC 810-10-25-42 through 25-44B.

For purposes of its accounting analysis, and as discussed above, Beam considered five of the six Orbital directors to be within a related party group with

Beam. As discussed below, Beam considered these relationships in concluding that the related parties do not share power as defined under the applicable accounting standards, and that Beam would not apply the related party “tiebreaker test.”

Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #5

As shown in the capitalization table above, [**]. For the purposes of the ASC 810 accounting analysis, Beam considered Arch to be a de facto agent and therefore a related party under ASC 810-10-25-43(c) of Beam because two members of Beam’s board of directors are affiliated with Arch. In addition, the Orbital Board Preferred Designee is affiliated with Arch and serves on the

Beam board of directors. Because the Orbital Board Preferred Designee is also a member of the Beam board of directors, for purposes of the accounting analysis, Beam also considered him to be a related party under ASC 810-10-25-43(c) of Beam. The a16z Designee is not a related party of Beam, including consideration of the de facto agent guidance.

Beam Therapeutics Inc. respectfully requests that the information contained in Request #5 be treated as confidential information and that the Commission provide timely notice to Terry-Ann Burrell, Chief Financial Officer and Treasurer, Beam Therapeutics Inc., 238 Main Street, Cambridge, MA 02142, phone 857-327-8775, before it permits any disclosure of the bracketed information contained in Request #5.

The following discussion sets forth Beam’s analysis under ASC 810-10-25-42 through 25-44B.

-

ASC

810-10-25-42

Beam concluded that the assessment in ASC

810-10-25-42 is not applicable because there is no single reporting entity (including with consideration of its related parties) having the power to direct the activities of Orbital that most significantly affect Orbital’s economic performance (i.e., that meets the test set forth in paragraph 810-10-25-38A(a)). Therefore, there is no “single decision maker.” The Orbital business is directed, managed, and controlled by the Orbital board and the decisions that most significantly impact the economic performance of Orbital require only simple majority approval of its board. Because, as noted above, no one party has the power to designate a majority of the directors to the Orbital board, no one party has the power to act as a single decision maker with respect to Orbital.

810-10-25-43

Please see Beam’s response to the Staff’s following question for Beam’s analysis of ASC 810-10-25-43.

810-10-25-44

The guidance of ASC 810-10-25-44 states in part (emphasis added):

The guidance in this paragraph shall be applicable for situations in which the conditions in paragraph 810-10-25-44A have been met or when power is shared for a VIE. In situations in which a reporting entity concludes that neither it nor one of its related parties has the characteristics in paragraph 810-10-25-38A but, as a group, the reporting entity and its related parties (including the de facto agents described in paragraph 810-10-25-43) have those characteristics, then the party within the related party group that is most closely associated with the VIE is the primary beneficiary. …..

The guidance in ASC 810-10-25-44 is inapplicable because the criteria of ASC 810-10-25-44A is not met and shared power is not present, as explained in this paragraph and below with respect to the analysis of ASC 810-10-25-44A. ASC 810-10-25-38D states that power “is shared if two or more unrelated parties together have the power to direct the activities of a

VIE that most significantly impact the VIE’s economic performance and if decisions about those activities require the consent of each of the parties sharing power.” As discussed above, all key decisions that most significantly affect

Orbital’s economic performance are made by a majority vote of its board at a meeting, or for administrative convenience, may be made by unanimous written consent of the Orbital board if a vote is not held. Therefore, not all parties in the related party group are required to approve the activities that most significantly affect Orbital’s economic performance. Hence, the power is not shared and the guidance in this paragraph is not applicable.

In reaching the conclusion that power is not shared, Beam considered interpretative guidance on the determination of shared power, all of which indicated that for shared power to exist, the unanimous consent of all parties is required for effective decisions. The following example from Section 7.4.2.2 of Deloitte & Touche LLP’s Consolidation Roadmap illustrates a similar scenario

(emphasis added):

Three related parties (A, B, and C) not under common control form Entity X (a VIE) and hold 25 percent,

35 percent, and 40 percent, respectively, of the entity’s voting interests. Decisions about the activities that most significantly affect the VIE’s economic performance require a simple majority vote of the voting interests.

Consequently, two of the three parties must agree on all of the decisions that most significantly affect the VIE’s economic performance. In this example, even though the related-party group holds 100 percent of the voting rights and economics, because X’s corporate governance does not require the consent of all the parties, power is not considered shared. Therefore, performance of the related-party tiebreaker test is not required, and no party will consolidate X.

Ernst & Young LLP’s Financial Reporting Developments, Consolidations describes shared power in section 9.3 as follows (emphasis added):

In certain instances, power can be shared by a group of entities that are related parties. We believe this will happen when the consent of each of the related parties is required to make the decisions about the significant activities…..

KPMG LLP’s Handbook, Consolidations describes shared power in Question 6.5.10 (emphasis added):

Interpretive response: Power is shared if:

[810-10-25-38D]

— two or more unrelated parties together meet the power criterion; and

— all decisions about the VIE’s most significant activities require the consent of each party (i.e. one party cannot unilaterally make decisions related to the VIE’s most significant activities).

PricewaterhouseCoopers LLP’s Consolidation describes shared power in Section 5.7.1 (emphasis added):

In situations where power over an entity’s most significant activities is shared among related parties, a qualitative analysis is required to determine which party within the related party group is most closely associated with the VIE. The party within the related party group that is most closely associated with the VIE is the primary beneficiary and is required to consolidate and disclose the impact of the VIE. Refer to CG 5.8 for further discussion related to the application of the related party tiebreaker test.

If no single party within the related party group has stated power, and a VIE’s significant activities require the consent of two or more related parties, a reporting entity must assess whether power is shared. As discussed in CG 5.2.4, shared power exists only when the unanimous consent of all parties believed to share power over a VIE’s economically significant activities is required. This concept is illustrated in Example CG 5-13.

Based on the above analysis, the guidance of ASC

810-10-25-44 is not applicable because shared power does not exist. The unanimous consent of all parties is not required to make decisions about the activities that most significantly affect Orbital’s economic performance.

810-10-25-44A

The guidance of ASC 810-10-25-44A states as follows:

In situations in which a single decision maker concludes, after performing the assessment in paragraph 810-10-25-42, that it does not have the characteristics in paragraph 810-10-25-38A, the single decision maker shall apply the guidance in paragraph

810-10-25-44 only when the single decision maker and one or more of its related parties are under common control and, as a group, the single decision maker and those related parties have the characteristics in paragraph 810-10-25-38A.

This guidance is also not applicable. As discussed above in the discussion of ASC 810-10-25-42, there is no single decision maker, and Beam is not under common control with any of the entities in the related party group.

810-10-25-44B

The guidance of ASC 810-10-25-44B provides as follows:

This paragraph applies to a related party group that has the characteristics in paragraph 810-10-25-38A only when both of the following criteria are met.

This paragraph is not applicable for legal entities that meet the conditions in paragraphs 323-740-15-3 and 323-740-25-1.

a.

The conditions in paragraph 810-10-25-44A are not met by a single decision maker and its related parties.

b.

Substantially all of the activities of the VIE either involve or are conducted on behalf of a single variable interest holder (excluding the single decision maker) in the single decision maker’s related party group.

The single variable interest holder for which substantially all of the activities either involve or are conducted on its behalf would be the primary beneficiary. The evaluation in (b) above should be based on a qualitative assessment of all relevant facts and circumstances. In some cases, when performing that qualitative assessment, quantitative information may be considered. This assessment is consistent with the assessments in paragraphs 810-10-1514(c)(2) and 810-10-15-17(d)(2).

Beam notes that criterion

(a) above is not applicable because there is no single decision maker. As described above, the Orbital board has complete discretion and authority over the management and control of Orbital. Criterion (b) does not require evaluation because criterion (a) is not met.

Because both criteria (a) and (b) above have to be met for the application of the guidance in

ASC 810-10-25-44B and criteria (a) has not been met, Beam concluded that it should not consolidate Orbital under the VIE model.

You state on page 77 of the 10-K that in addition to your CEO and President being members of the board of directors of Orbital, two of your directors affiliated with ARCH Venture Partners are members of the board of directors of Orbital. Tell us how you considered these directors in your determination of whether or not you are the primary beneficiary and whether or not these directors are considered de facto agents pursuant to ASC 810-10-25-43.

Beam considered the composition of Orbital’s board of directors in its primary beneficiary analysis. To restate the above conclusions, Beam’s CEO serves on Orbital’s board of directors as the Beam Designee. Additionally, Beam’s President serves on Orbital’s board of directors as the Orbital CEO Designee. Beam considered the definition of related parties for purposes of applying the ASC 810 accounting analysis to include de facto agents pursuant to ASC 810-10-25-43, which states that officers, employees and members of the governing board of the reporting entity are considered de facto agents. One of the Arch Designees also serves as a member of Beam’s board of directors. Accordingly, both of the Arch Designees are de facto agents of Beam. Additionally, the Orbital Board Preferred Designee is both a member of Beam’s board of directors and a venture partner with Arch and is considered a de facto agent of Beam. As a result, two of the six Orbital board seats are controlled by Beam and three are de facto agents, and therefore considered to be related parties under the ASC 810 accounting analysis. The sixth board seat, designated by a16z, is neither a related party nor a de facto agent of Beam. These facts were considered in Beam’s analysis of ASC 810-10-25-44 through 44B as described above, along with the fact that power is not shared among related parties.

Stock Purchase Agreement for purchase of 75.0 million shares of Orbital common stock with a fair value of $25.5 million

Key governance documents for Orbital (e.g., articles of incorporation, bylaws, investor rights agreement and voting agreement) to the extent they contain information relevant to an analysis under ASC 810.

Beam acknowledges the

Staff’s request and respectfully advises the Staff that in response to this comment, the confidential documents requested are being provided directly to the Staff by Wilmer Cutler Pickering Hale and Dorr LLP (“WilmerHale”) under separate cover on a confidential and supplemental basis pursuant to Rule 12b-4 under the Securities Exchange Act of 1934, as amended (“Rule 12b-4”). In accordance with Rule 12b-4, such materials are being provided together with a request that these materials be destroyed promptly following completion of the Staff’s review thereof. Such materials are not, and will not be, filed with or deemed to be part of the Form 10-K, including any amendments thereto. By separate letter, request for confidential treatment of these materials pursuant to the provisions of 17

C.F.R. §200.83 has been made by WilmerHale.

Read in the reply

Also in this review: closing letter, 2023-10-12

Form S-1

2019-08-23 to 2020-01-30 · 17 questions · 4 letters from the SEC, 4 from the company
No closing letter
Critical estimatesExecutive payResults discussion (MD&A)Legal and contingenciesDerivatives and hedging
Prospectus Summary, page 1
SEC asked (1)
Please provide support for the statements below. In this regard, please explain how you have "demonstrated" certain abilities when none of your product candidates are in clinical stages of development: • "we have demonstrated the ability to create the naturally-occurring 'Makassr' variant of hemoglobin," on pages 4 and 131; • "[w]e have demonstrated the ability of base editors to perform simultaneous multiplex
Rest of the question

editing with very high efficiencies and without any detectable chromosomal rearrangements," on pages 4 and 123; • "[o]our AATD base editing program has demonstrated the ability to directly correct the E342K point mutation, potentially addressing both the lung and liver components of the disease," on page 4; • "[o]ur base editors have demonstrated the ability to repair the two most prevalent mutations that cause the disease," on page 4; and • "[o]ur base editing approach, delivered through AAV viral vectors, has demonstrated the ability to repair the G1961E point mutation," on page 5.

BEAM answered

No numbered answer found in the reply. Read the reply ↗

Our Portfolio, page 2
SEC asked (2)
Please add columns in your portfolio table here and on pages 113 and 124 to show all phases of the FDA approval process.
BEAM answered

No numbered answer found in the reply. Read the reply ↗

Implications of being an emerging growth company, page 7
SEC asked (3)
Please provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
BEAM answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 86
SEC asked (4)
We note your disclosure that you intend to use net proceeds for continued research and development of your portfolio of base editing programs, for IND-enabling studies and the potential initiation of clinical studies, and for continued advancement of your platform technologies and discovery-stage research for other potential programs.
Rest of the question

Please specify how far in the development of each of the listed clinical trials or programs you expect to reach with the proceeds of the offering. If any material amounts of other funds are necessary to accomplish the specified purposes, state the amounts and sources of other funds needed for each specified purpose and the sources. Refer to Instruction 3 to Item 504 of Regulation S-K.

BEAM answered

No numbered answer found in the reply. Read the reply ↗

Critical accounting policies and significant judgments · Share-based compensation, page 105
SEC asked (5)
Once you have an estimated offering price range, please explain to us the reasons for any differences between recent valuations of your common shares leading up to the planned initial public offering and the midpoint of your estimated offering price range. This information will help facilitate our review of your accounting for equity issuances, including stock compensation.
BEAM answered
Estimated Preliminary Initial Public Offering Price Range

The Company supplementally advises the Staff that, while not yet reflected in the Registration Statement, based on discussions with the

Company’s board of directors (the “Board”) and reflecting input from the lead underwriters (the “Underwriters”) of the Company’s proposed initial public offering of shares of its common stock

(“IPO”), if the Company were to commence marketing of the transaction today, the Company presently anticipates that the estimated price range would be approximately $[***] per share to $[***] per share
Rest of the answer

(the

“Preliminary IPO Price Range”), with a midpoint of approximately $[***] per share (the “Preliminary Assumed IPO Price”), before giving effect to an anticipated reverse stock split. The Company advises the Staff that the final range to be included in a pre-effective amendment to the Registration Statement will include a price range of no more than $2.00, if the maximum price is less than $10.00 per share, or

20% of the high end of the range, if the maximum price is greater than $10.00 per share, unless otherwise approved by the Staff.

CONFIDENTIAL TREATMENT

REQUESTED BY BEAM THERAPEUTICS INC.

The Company’s final range to be included in a pre-effective amendment to the Registration Statement remains under discussion between the Company and the Underwriters, and a bona fide price range will be included in an amendment to the Registration

Statement prior to any distribution of the preliminary prospectus in connection with the Company’s road show.

Summary of Recent Restricted

Stock Grants, Option Grants and Common Share Valuation

As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by its Board as of the date of each option and restricted stock grant, with input from management, considering third-party valuations of the common stock when obtained as well as the Board’s assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation

(the “Guide”).

Consistent with the Guide, a third-party valuation firm prepared valuations of the

Company’s common stock using a hybrid method (the “Hybrid Method”) between the Probability Weighted Expected Returns Method (“PWERM”) and the Option Pricing Model (“OPM”).

The Hybrid Method was used to estimate the probability weighted value across multiple scenarios, but using the OPM to estimate the allocation of value within one or more of those scenarios. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under OPM, the shares of common stock have value only if the funds available for distribution to shareholders exceeded the value of the preferred share liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The PWERM is a scenario-based methodology that estimates the fair value of common stock based on an analysis of future values for a company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock.

The following table sets forth, by grant date, the number of common shares subject to options and restricted common stock awards granted from January 1, 2018 through August 31, 2019, the per share exercise price of the options or value of restricted stock, the per share fair value of the common stock on each grant date and the per share estimated value of awards on each grant date:

Grant Date

Type of Award

Per Share Exercise

Price of Options or

Value of

Restricted Stock

Per Share

Common Stock on Grant Date

Number of

Common Shares

Underlying

Grant

January 8, 2018

$

0.11

3,815,647

March 1, 2018

Stock Options

0.15

75,000

1,742,423

May 8, 2018

4,590,909

July 13, 2018

0.23

4,188,225

September 7, 2018

0.90

(1)

151,515

September 13, 2018

1,827,800

September 25, 2018

7,997,066

February 13, 2019

0.94

1.43

3,363,589

May 16, 2019

1.61

1.80

2,204,000

May 17, 2019

2,784,000

May 24, 2019

965,500

May 31, 2019

104,500

July 25, 2019

2.65

586,000

August 30, 2019

3.05

224,000

August 31, 2019

1,750,000

In June, July, and August 2019, the Company performed retrospective fair value assessments and concluded that the fair value of its common stock underlying stock options that it granted in September 2018, February and May 2019 were $0.90, $1.43 and $1.80 per share, respectively, solely for accounting purposes. This reassessed value was based, in part, upon third-party valuations of the Company’s common stock prepared on this date on a retrospective basis. Third-party valuations were prepared using a Hybrid Method, which considered an initial public offering scenario, a recent transaction method and trade sale scenarios to determine the Company’s enterprise value.

The Board’s determination of fair value was based, in part, on the results of ASC 718 contemporaneous third-party valuations of the Company’s common stock performed June 30, 2017 (the “June 2017 Valuation”), March 26, 2018 (the “March 2018 Valuation’),

June 11, 2018 (the “June 2018 Valuation”) and retrospective ASC 718 valuations prepared as of September 25, 2018 (the “September 2018 Retrospective Valuation”), December 1, 2018 (the “December 2018

Retrospective Valuation”), and April 30, 2019 (the “April 2019 Retrospective Valuation’)

January 8, 2018 Restricted Stock Awards. The Board determined that the fair value of the

Company’s common stock was $0.11 per share as of January 8, 2018 based on input from management, the objective and subjective factors disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the June 2017 Valuation. The June 2017 Valuation utilized a recent transaction method under the market approach and an OPM to determine the value of the Company’s common stock. The market approach was selected as the Company had closed an initial tranche of Series A Preferred stock in June 2017 at $1.00 per share. This approach priced the common stock off the Series A Preferred price by considering the economic and control rights of the preferred shareholders versus the common shareholders. The June 2017 Valuation then applied a discount for lack of marketability of 35.0% to arrive at an indication of value of the Company’s common stock of $0.11 per share.

March 1, 2018 and May 8, 2018 Option

Grants and Restricted Stock Awards. The Board determined that the fair value of the Company’s shares of common stock was $0.15 per share as of March 1, 2018 and May 8, 2018 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the March 2018 Valuation. The March 2018 Valuation utilized a recent transaction method under the market approach and an OPM to determine the value of the Company’s common stock. The market approach was selected as the Company had closed a second tranche of Series A Preferred stock in February 2018 at $1.00 per share. This approach priced the common stock off the Series A Preferred price by considering the economic and control rights of the preferred shareholders versus the common shareholders. The March 2018 Valuation then applied a discount for lack of marketability of 35.0% to arrive at an indication of value of the Company’s common stock of $0.15 per share.

July 13, 2018 Option

Grants. The Board determined that the fair value of the Company’s shares of common stock was $0.23 per share as of July 13, 2018 based on input from management, the objective and subjective factors (disclosed on page 110 of the

Registration Statement) that it believed were relevant, and the results of the June 2018 Valuation. The June 2018 Valuation utilized a recent transaction method under the market approach and an OPM to determine the value of the Company’s common stock. The market approach was selected as the Company had closed an initial tranche of Series A-2 Preferred stock in June 2018 at $1.50 per share in an arm’s length transaction. This approach priced the common stock off the Series A-2 Preferred price by considering the economic and control rights of the preferred shareholders versus the common shareholders. The June 2018 Valuation then applied a discount for lack of marketability of 35.0% to arrive at an indication of value of the Company’s common stock of $0.23 per share.

September 7, 2018, September 13, 2018 and

September 25, 2018 Option Grants and Restricted Stock Awards. The Board determined that the retrospective fair value of the Company’s shares of common stock was $0.90 per share as of September 7,

2018, September 13, 2018 and September 25, 2018 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the September

2018 Retrospective Valuation. The September 2018 Retrospective Valuation was prepared taking into account the Company’s progress, the Company’s progress toward closing the final tranche of its Series

A-2 financing, the Blink Merger which closed on September 25, 2019, new lab and office space the Company was set to occupy in October 2018 and its prospects for a potential initial public offering. The

September 2018 Retrospective Valuation utilized the Hybrid Method to determine the value of the Company’s common stock. The Hybrid Method contemplated several scenarios: (i) a near-term initial public offering of the Company’s common stock, (ii) a long-term initial public offering of the Company’s common stock, (iii) a recent transaction method under the market approach and (iv) the sale of the Company at or below the preferred stock liquidation preference.

The September 2018 Retrospective Valuation considered the likelihood of which the

Company would seek a near-term initial public offering based on the Company’s status, which was determined to be 5.0%. A long-term initial public offering based on guideline initial public offering transactions was utilized with a 45.0% scenario weighting. Under the market approach, a recent transaction method was utilized to determine the equity value. The likelihood of this scenario was determined to be 30.0%. The fourth scenario was the sale at or below the preferred shares liquidation preference, which would yield no value to the common stock. This scenario was weighted at 20.0%. The September 2018 Retrospective Valuation then applied a discount for lack of marketability of 17.0% under the near-term initial public offering scenario, 30.0% under the long-term initial public offering scenario, and 37.0% under the trade sale scenario. The weightings of 5.0% to the near-term initial public offering scenario, 45.0% to the long-term initial public offering, 30.0% to the recent transaction method scenario and 20.0% to the sale at or below the preferred shares liquidation preference resulted in a valuation of the Company’s common stock of $0.90 per share.

February 13, 2019 Option Grants. The Board determined that the retrospective fair value of the Company’s shares of common stock was $1.43 per share as of February 13, 2019 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the

December 2018 Retrospective Valuation. The December 2018 Retrospective Valuation was prepared taking into account the Company’s progress, including the sale of Series B Preferred Stock from November 2018 to February 2019 at $3.36 per share to new and existing investors in arm’s length transactions, and its prospects for a potential initial public offering. The December 2018 Retrospective Valuation utilized the Hybrid Method to determine the value of the Company’s common stock.

The Hybrid Method contemplated several scenarios: (i) a near-term initial public offering of the Company’s common stock, (ii) a long-term initial public offering of the Company’s common stock, (iii) a recent transaction method under the market approach and (iv) the sale of the Company at or below the preferred stock liquidation preference. The December 2018 Retrospective Valuation considered the likelihood of which the Company would seek a near-term initial public offering based on the Company’s status, which was determined to be 5.0%. A long-term initial public offering based on guideline initial public offering transactions was utilized with a 45.0% scenario weighting. Under the market approach scenario, a recent transaction method was utilized to determine the equity value. The likelihood of this scenario was determined to be 30.0%. The fourth scenario was the sale at or below the preferred shares liquidation preference, which would yield no value to the common stock. This scenario was weighted at 20.0%. The December 2018 Retrospective Valuation then applied a discount for lack of marketability of 17.0% under the near-term initial public offering scenario, 20.0% under the long-term initial public offering scenario, and 34.0% under the trade sale scenario. The weightings of 5.0% to the near-term initial public offering scenario, 45.0% to the long-term initial public offering, 30.0% to the recent transaction method scenario and 20.0% to the sale at or below the preferred shares liquidation preference resulted in a valuation of the Company’s common stock of $1.43 per share.

May 16, 2019, May 17, 2019, May 24, 2019 and

May 31, 2019 Option Grants. The Board determined that the retrospective fair value of the Company’s shares of common stock was $1.80 per share as of May 16, 2019, May 17, 2019, May 24,

2019 and May 31, 2019 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the April 2019 Retrospective Valuation. The

April 2019 Retrospective Valuation was prepared taking into account the Company’s progress and its prospects for a potential initial public offering, which included preparing to request approval of the Company’s Board of Directors to proceed with IPO activities at the May 17, 2019 Board of Directors meeting and taking steps toward an IPO organization meeting. The April 2019 Retrospective Valuation utilized the Hybrid Method to determine the value of the Company’s common stock. The Hybrid Method contemplated several scenarios: (i) a near-term initial public offering of the Company’s common stock, (ii) a long-term initial public offering of the Company’s common stock, (iii) a recent transaction method under the market approach and (iv) the sale of the Company at or below the preferred stock liquidation preference. The April 2019 Retrospective Valuation considered the likelihood of which the Company would seek a near-term initial public offering based on the Company’s status, which was determined to be 25.0%. A long-term initial public offering based on guideline initial public offering Transactions was utilized with a 25.0% scenario weighting. Under the market approach scenario, a recent transaction method was utilized to determine the equity value. The likelihood of this scenario was determined to be 30.0%. The fourth scenario was the sale at or below the preferred shares liquidation preference, which would yield no value to the common stock. This scenario was weighted at 20.0%. The April 2019 Retrospective Valuation then applied a discount for lack of marketability of 10.0% under the near-term initial public offering scenario, 17.0% under the long-term initial public offering scenario, and 30.0% under the trade sale scenario. The weightings of 25.0% to the near-term initial public offering scenario, 25.0% to the long-term initial public offering, 30.0% to the recent transaction method scenario and 20.0% to the sale at or below the preferred shares liquidation preference resulted in a valuation of the Company’s common stock of $1.80 per share.

July 25, 2019 Option Grants. The Board determined that the fair value of the Company’s shares of common stock was $2.65 per share as of July 25, 2019 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the July 2019 Valuation.

The July 2019 Valuation was prepared taking into account the Company’s progress and its prospects for a potential IPO which included an IPO organization meeting on June 20, 2019 and preparation of an S-1 which was confidentially filed on July 26, 2019. The July 2019 Valuation utilized the Hybrid Method to determine the value of the Company’s common stock. The Hybrid Method contemplated several scenarios: (i) a near-term initial public offering of the Company’s common stock, (ii) a long-term initial public offering of the Company’s common stock, (iii) a trade sale scenario and (iv) the sale of the Company at or below the preferred stock liquidation preference. The July 2019 Valuation considered the likelihood of which the Company would seek a near-term initial public offering based on the Company’s status, which was determined to be 50.0%. A long-term initial public offering based on guideline initial public offering transactions was utilized with a 10.0% scenario weighting. Under the trade sale scenario, a guideline transaction method was utilized to determine the equity value. The likelihood of this scenario was determined to be 30.0%. The fourth scenario was the sale at or below the preferred shares liquidation preference, which would yield no value to the common stock. This scenario was weighted at 10.0%. The July 2019

Valuation then applied a discount for lack of marketability of 5.0% under the near-term initial public offering scenario, 15.0% under the long-term initial public offering scenario, and 25.0% under the trade sale scenario. The weightings of 50.0% to the near-term initial public offering scenario, 10.0% to the long-term initial public offering, 30.0% to the trade sale scenario and 10.0% to the sale at or below the preferred shares liquidation preference resulted in a valuation of the

Company’s common stock of $2.65 per share.

August 30, 2019 and August 31,

2019 Option Grants. The Board determined that the fair value of the Company’s shares of common stock was $3.05 per share as of August 30, 2019 and August 31, 2019 based on input from management, the objective and subjective factors (disclosed on page 110 of the Registration Statement) that it believed were relevant, and the results of the August 2019 Valuation. The August 2019 Valuation was prepared taking into account the Company’s progress and its prospects for a potential IPO including response to initial comments received from the Commission and pending submission of Amendment No. 1 to its draft confidential registration statement on Form S-1, which occurred on September 9, 2019. The August 2019 Valuation utilized the Hybrid Method to determine the value of the Company’s common stock. The Hybrid Method contemplated several scenarios: (i) a near-term initial public offering of the

Company’s common stock, (ii) a long-term initial public offering of the Company’s common stock, (iii) a trade sale scenario and (iv) the sale of the Company at or below the preferred stock liquidation preference. The August

2019 Valuation considered the likelihood of which the Company would seek a near-term initial public offering based on the Company’s status, which was determined to be 65.0%. A long-term initial public offering based on guideline initial public offering transactions was utilized with a 10.0% scenario weighting. Under the trade sale scenario, the guideline transaction method was utilized to determine the equity value. The likelihood of this scenario was determined to be

15.0%. The fourth scenario was the sale at or below the preferred shares liquidation preference, which would yield no value to the common stock. This scenario was weighted at 10.0%. The August 2019 Valuation then applied a discount for lack of marketability of 5.0% under the near-term initial public offering scenario, 15.0% under the long-term initial public offering scenario, and 25.0% under the trade sale scenario The weightings of 65.0% to the near-term initial public offering scenario, 10.0% to the long-term initial public offering, 15.0% to the trade sale scenario and 10.0% to the sale at or below the preferred shares liquidation preference resulted in a valuation of the Company’s common stock of $3.05 per share.

Comparison of the Most Recent Valuation and the Preliminary IPO Price Range

As is typical in an initial public offering, the Preliminary IPO Price Range for the IPO was not derived using a formal determination of estimated fair value, but was determined based on discussions between the Company and the Underwriters. Prior to September 23, 2019, the Company and the Underwriters had not had any specific discussions regarding the Preliminary IPO Price

Range. Among the factors that the Company considered in setting the Preliminary IPO Price Range were the following:

• an analysis of the typical valuation ranges seen in recent initial public offerings for preclinical-stage biopharmaceutical companies;

the general condition of the securities markets and the recent market prices of, and the demand for, publicly traded common stock of generally comparable companies;

the recent performance of U.S. initial public offerings of generally comparable companies;

estimates of business potential and earnings prospects for the Company and the industry in which it operates;

the Company’s financial position and prospects;

an assumption that there would be a receptive public trading market for pre-commercial, preclinical-stage biopharmaceutical companies such as the Company; and an assumption that there would be sufficient demand for shares of the Company’s common stock to support an offering of the size contemplated by the Company.

The Company respectfully submits that the difference between the

August 2019 Valuation price and the Preliminary Assumed IPO Price is primarily attributable to the following factors:

The Preliminary IPO Price Range is based only upon a scenario in which the Company completes the IPO and is not probability weighted, in contrast to the Company’s August 2019 valuation of common stock, which considered other potential exit scenarios, which would have resulted in lower value of its common stock than an IPO. If the Company had applied a weighting of 100% to the near-term IPO scenario, the fair value of the Company’s common stock in the August 2019 Valuation would have been $[***] per share (before giving effect to any discount for lack of marketability).

The Preliminary IPO Price Range assumes that the IPO has occurred and that a public market for the Company’s common stock has been created, and, therefore, excludes any discount for lack of marketability of the Company’s common stock. As described above, a discount for lack of marketability was applied in the third-party valuation reports.

The Company’s shares of preferred stock currently have substantial economic rights and preferences over its shares of common stock. Upon the closing of an IPO, all outstanding shares of preferred stock will convert into shares of common stock, thus eliminating the superior economic rights and preferences of the Company’s shares of preferred stock as compared to its shares of common stock.

The successful completion of the IPO would strengthen the Company’s balance sheet, provide access to additional public equity going forward, increase the Company’s strategic flexibility and provide enhanced operational flexibility to potentially obtain regulatory approval for and commercialize its product candidates.

Input received from the Underwriters, including further discussions that took place during the week of

September 23, 2019 with senior management of the Company and its Board, and following feedback from qualified potential investors obtained during testing-the-waters meetings in September 2019.

In conclusion, the Company respectfully submits that the difference between the recent valuation of its shares of common stock used in connection with the option grants for financial reporting purposes and the Preliminary Assumed IPO Price (i.e., the midpoint of the Preliminary IPO Price Range) is reasonable in light of all of the considerations outlined above. In addition, the Company will continue to update its disclosure for all equity-related transactions, if any, through the effective date of the Registration Statement. Based on the foregoing, the Company respectfully seeks confirmation that the Staff has no further comments with respect to the matters discussed in this Letter.

Because of the financially sensitive nature of the estimated price range, the Company requests confidential treatment under 17 C.F.R. § 200.83 of the contents of this letter and has submitted a separate request for confidential treatment in accordance therewith to the Commission’s Office of Freedom and Information Privacy Act Operations. Pursuant to Rule 418 under the Securities Act of 1933, as amended (the “Securities Act”), the information contained in this letter is being provided to the Commission on a confidential supplemental basis only and is not to be filed with or deemed part of the Registration Statement. The Company respectfully requests that the Staff return the unredacted version of this letter to the

Company pursuant to Rule 418 of the Securities Act once the Staff has completed its review. We have provided a self-addressed stamped envelope for this purpose. Kindly acknowledge receipt of this letter by stamping the enclosed copy of this letter and returning it in the envelope provided.

Read in the reply
Business, page 112
SEC asked (6)
We note your description of the Collaboration and License Agreement with Verve on page F-38. If this agreement is material, please file it as an exhibit to the registration statement and describe its material terms in the business section. In addition, disclose the milestone and royalties payments under the agreement referenced on page F-39.
Rest of the question

Approach 1: Recreate naturally-occurring protective HPFH mutations to evaluate HbF, page 129

BEAM answered

No numbered answer found in the reply. Read the reply ↗

Business, page 112
SEC asked (7)
Please provide support for your statement that your "base editor program uses a precise, direct editing strategy that is validated by human genetics." We note that you have not conducted any clinical trials, yet state that your strategy has been validated by human genetics.
BEAM answered

No numbered answer found in the reply. Read the reply ↗

License Agreement with The President and Fellows of Harvard College, page 147
SEC asked (8)
We note your reference to "low double digits" describing royalties or other types of payments on pages 149 and 153. Please revise your disclosure to narrow the royalty range in each of the referenced cases to no more than ten percentage points (for example, between twenty and thirty percent).
BEAM answered

No numbered answer found in the reply. Read the reply ↗

License Agreement with Editas Medicine, Inc. , page 149
SEC asked (9)
Please disclose the aggregate milestone payments under the Editas agreement. We note your reference to milestone payments on page 150. 8. Blink Therapeutics, page F-27
BEAM answered

No numbered answer found in the reply. Read the reply ↗

License Agreement with Editas Medicine, Inc. , page 149
SEC asked (10)
Please provide us an analysis supporting your accounting treatment for the share exchange with Blink Therapeutics, which resulted in a $49.5 million loss, as well as expenses associated with the other exchange transactions described on page F-28. In particular, explain your consideration of guidance governing common control transactions. Refer us to the technical literature upon which you relied.
Rest of the question

Notes to Consolidated Financial Statements 9. Redeemable convertible preferred stock, page F-28

BEAM answered

No numbered answer found in the reply. Read the reply ↗

License Agreement with Editas Medicine, Inc. , page 149
SEC asked (11)
Please provide us an analysis supporting your accounting treatment for the reclassification of the tranche liability, associated with "committed" investors, to the carrying value of the Series A-2 Preferred shares, as well as the $5.7 million loss recognized upon the issuance of Series A-2 Preferred shares to "additional" investors. Refer us to the technical literature upon which you relied.
BEAM answered

No numbered answer found in the reply. Read the reply ↗

Part II · Exhibit index, page II-5
SEC asked (12)
Please file the employment agreements with your named executive officers described on page 186 or tell us why you believe they are not required to be filed.
BEAM answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary, page 1
SEC asked
We note your response to comment 1 and your revised disclosure. For each of the referenced statements please add balancing disclosure to convey that there is no guarantee that you will be able to demonstrate the same results in clinical trials.
Rest of the question

In the alternative, please remove the following statements: • "we have demonstrated the ability to create the naturally-occurring 'Makassr,'" on pages 4 and 136; • "[w]e have demonstrated the ability of base editors to perform simultaneous multiplex editing with very high efficiencies and without any detectable chromosomal rearrangements," on pages 4 and 138; • "[o]our AATD base editing program has demonstrated in cell lines the ability to directly correct the E342K point mutation, potentially addressing both the lung and liver components of the disease," on page 4; • "[o]ur base editors have demonstrated in cell lines the ability to repair the two most prevalent mutations that cause the disease," on page 4; and • "[o]ur base editing approach, delivered through AAV viral vectors, has demonstrated in cell lines the ability to repair the G1961E point mutation," on page 5.

BEAM answered
Based on the Staff’s comment, the Company has revised the Registration Statement for each of the referenced statements above to convey that there is no guarantee that the Company will be able to demonstrate the same results in clinical trials.
Read in the reply
License and collaboration agreement, page 209
SEC asked (1)
Please expand your discussion of the collaboration and license agreement with Prime Medicine, Inc. to quantify aggregate milestone payments by type of event (e.g. clinical stage as compared to commercial stage) and a royalty rate range that does not exceed ten percentage points.
BEAM answered
1: Based on the Staff’s comment, the Company has revised the Registration Statement on page 214 to quantify aggregate milestone payments and royalty ranges for the collaboration and license agreement with Prime Medicine, Inc.
Read in the reply
General
SEC asked (2)
We note that Section 8 of your amended and restated bylaws grants exclusive jurisdiction to federal courts for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933. Please clearly and prominently describe this provision in your prospectus, clearly describe any risks or other impacts on the investors, and address any uncertainty about the enforceability of the provision.
BEAM answered
Based on the

Staff’s comment, the Company has revised the Registration Statement on pages 83, 84 and 222 to describe the provision in the Company’s amended and restated bylaws that grants exclusive jurisdiction to federal courts for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933. The Company advises the Staff that the risks and impact on investors and the uncertainty about the enforceability of the provision is disclosed on pages 83 and 84 of the Registration Statement.
Read in the reply
SEC asked (1)
Please provide us calculations supporting “Pro forma net tangible book value per share of common stock as of September 30, 2019” of $3.24 per share and “Pro forma as adjusted net tangible book value per share of common stock after the offering” of $4.78 per share.
Rest of the question

Also, explain your basis for including redeemable convertible stock of $298,786 in determining “Historical net tangible book value per share of common stock at September 30, 2019.” In addition, explain your basis for including 3,043,669 shares of unvested restricted stock that is “not issued and outstanding for accounting purposes and not included in our consolidated financial statements.” Refer us to the technical guidance upon which you relied and revise your presentation accordingly.

BEAM answered
In response to the Staff’s comment, the Company has revised the Registration Statement on pages 92 and 93 to exclude redeemable convertible stock of $298,786 in determining “Historical net tangible book deficit per share of common stock at September 30, 2019” and to exclude the 3,043,669 shares of unvested restricted from the calculations of “Historical net tangible book value per share of common stock as of September 30, 2019,” “Pro forma net tangible book value per share of common stock as of

September 30, 2019,” and “Pro forma as adjusted net tangible book value per share of common stock
Rest of the answer

after the offering.”

In response to the

Staff’s comment, below are the calculations supporting the revised calculation of “Historical net tangible book deficit per share”, “Pro forma net tangible book value per share of common stock as of September 30, 2019” and

“Pro forma as adjusted net tangible book value per share of common stock after the offering.”

Historical net tangible deficit per share

Total Assets

$

170,553

Less: Total Liabilities

(43,832

)

Less: Preferred Stock

(298,786

Net Tangible Book Value

(172,065

Common Stock outstanding as of September 30, 2019

6,903,654

(excludes 3,043,669 unvested restricted shares

Historical net tangible deficit per share as of September 30, 2019

(24.92

Read in the reply
General
SEC asked (2)
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Exchange Act.
Rest of the question

In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

BEAM answered
The Company acknowledges the Staff’s comment and advises that the

Company’s forum selection provision as revised explicitly does not apply to claims arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. In response to the Staff’s comment, the Company has revised its amended and restated certificate of incorporation and pages 84 and 222 of the Registration Statement to clarify that this provision does not apply to claims arising under the Securities Act of 1933, as amended, or the Securities

Exchange Act of 1934, as amended.
Rest of the answer

The Company undertakes to include similar disclosure in its Annual Report on Form 10-K and any other applicable future filings with the Commission.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 18 letters filed since 2019-08-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BEAM/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.